DaVita healthCare Partners Inc Stock News

Medtronic plc (NYSE: MDT) and DaVita Inc (NYSE: DVA) intend to form a new, independent kidney care-focused medical device company (NewCo). NewCo will focus on developing a broad suite of novel kid

Investors remain optimistic about DaVita (DVA) due to strength in its DaVita Kidney Care and impressive overseas growth.

With steady revenues and a predictable earnings profile, DaVita is a perfect example of a stock which could add stability to investors' portfolios during periods of volatility. While the company has a

DaVita Inc. (NYSE:DVA ) Q1 2022 Results Conference Call May 5, 2022 5:00 PM ET Company Participants Joel Ackerman - CFO and Treasurer Javier Rodriguez - CEO Conference Call Participants Kevin Fischbec

DaVita HealthCare (DVA) delivered earnings and revenue surprises of -12.97% and 2.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

DaVita Inc. shares dropped in the extended session Thursday after the dialysis-service provider's earnings fell short of Wall Street estimates as the company said COVID-19 factors and higher wages din

Investors around the world are making the journey to Omaha, Nebraska to attend Berkshire Hathaway's ( BRK.A , Financial)( BRK.B , Financial) annual shareholder meeting this weekend, which is being hel

DENVER , April 21, 2022 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Thursday, May 5, 2022, at 5 p.m.

A jury in Denver, Colorado, acquitted dialysis provider DaVita and its former CEO Kent Thiry on Friday of charges that they conspired with competitors not to hire each other's employees.

LHC Group's (LHCG) latest joint venture with Archbold Medical Center to enhance home health services in Thomasville and across South Georgia.

DaVita (DVA) continues to gain traction from its strong international presence and solid DaVita Kidney Care business. However, integration risks are a woe.

DaVita (DVA) continues to gain traction from its strong international presence and solid DaVita Kidney Care business. However, integration risks are a woe.

Let's see if DaVita (DVA) stock is a good choice for value-oriented investors right now from multiple angles.

Let's see if DaVita (DVA) stock is a good choice for value-oriented investors right now from multiple angles.

RESEARCH TRIANGLE PARK, N.C. , March 1, 2022 /PRNewswire/ -- Pathalys Pharma, Inc., a private, late-stage biopharma company committed to the development and commercialization of a range of best-in-class therapies for patients with chronic kidney disease (CKD), today announced its formation made possible through initial seed financing from DaVita Venture Group, part of DaVita Inc. (NYSE: DVA ), and Catalys Pacific. Pathalys launches with a novel clinical-stage asset, upacicalcet, that was acquired through a license granted by EAPharma for exclusive rights to the development and commercialization of the product, worldwide outside of Japan and Asia . LQDA ) has been appointed CEO at Pathalys and will serve on the company''s board of directors." alt="Neal Fowler, a seasoned industry veteran and former Chief Executive Officer (CEO) at Liquidia Corporation (NASDAQ: LQDA ) has been appointed CEO at Pathalys and will serve on the company''s board of directors."> "We are excited about this opportunity to join forces with DaVita, a recognized leader in kidney care, in an effort to advance multiple best-in-class therapies for patients with CKD who are in need of better treatments – beginning with upacicalcet," said BT Slingsby, M.D., Ph.D., M.P.H., founder and Executive Chairman of Pathalys and Managing Partner, Catalys Pacific.